Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community Why was fluridil abandoned and never made past phase 2?

      in Chat  4 upvotes 4 years ago
      Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.

      community ET-02 Now Recruiting in Texas for Phase 1

      in Research/Science  20 upvotes 1 year ago
      Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

      community It's probably RU58841, which is weak in adenosine.

      in Treatment  13 upvotes 1 year ago
      The conversation is about using adenosine, finasteride, and minoxidil for hair loss treatment. The user ordered a 0.75% adenosine solution and is currently using finasteride 1mg and minoxidil 5%.

      community Low Testosterone after taking finastreide

      in Finasteride  45 upvotes 11 months ago
      A 19-year-old experienced significantly low testosterone levels after one month of taking finasteride. Suggestions included checking test units, retesting, and exploring other potential causes.

      community second shed on dutasteride, but a woman

      in Finasteride/Dutasteride  2 upvotes 1 year ago
      A woman experiencing hormonal hair loss is on dutasteride and bicalutamide, which initially improved her hair, but she is now experiencing a second shedding phase with significant short hair loss. Despite normal hormone levels and no deficiencies, she is unsure if this shedding is normal and seeks advice.

      community Has anyone else seen this encouraging verteporfin case study?

      in Progress Pictures  35 upvotes 2 years ago
      The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.